Ipsen, an innovation-driven global specialty pharmaceutical group, today announced an agreement whereby Ipsen grants the Menarini Group the exclusive licence rights to Adenuric® (febuxostat) in 41 countries. Ipsen retains co-promotion rights for Adenuric® in France.
the details can be read here.
No comments:
Post a Comment